At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- no intervention (other)
- How long the study runs
- Study runs about 39 months (dates as stated)
- About the drug or intervention
- no intervention — other: not applicable, this is an observational retrospective data analysis study; no interventions in the study
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- Not specified
- Who
- All
- Number of participants
- 52,121
- Started
- 2023-08-21
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for attr amyloidosis
- • Clinical study - 52,121 participants
- • The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented
Who can take part?
- • Adults
- • Diagnosed with attr amyloidosis
Where?
- • London - Research Site
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.
More detail
This retrospective, observational, longitudinal, multi-country cohort study aims to describe characteristics, treatment patterns, and outcomes in ATTR amyloidosis patients. Primary objectives: Describe patient characteristics (for example demographics, family history of ATTR, key comorbidities and humanistic outcomes (e.g. Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments), treatment patterns, and disease outcomes. Characterize and quantify the healthcare resource utilization (HCRU) in ATTR amyloidosis patients who will be followed post-index until the end of follow-up. Secondary objectives: Describe demographics, clinical characteristics and HCRU in ATTR amyloidosis patients prior to diagnosis.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: Not specified
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓Patients aged \>18 years at study index date AND
- ✓A reported diagnosis code for amyloidosis OR
- ✓A claim for ATTR-specific treatment OR
- ✓A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR
Who cannot take part
- ✗Evidence of primary (AL) and secondary (AA) amyloidosis AND/OR
See the full criteria
Where Is This Study? (1 UK site)
Research Site
London, United Kingdom
How to Get in Touch
AstraZeneca Clinical Study Information Center
Sponsor contactCONTACT